Related Experiment Video
Updated: May 2, 2026
04:33
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.8K
Do manualized treatments for depression reduce insomnia symptoms?
Adriana Yon1, Forrest Scogin, Elizabeth A DiNapoli
1University of Alabama.
Journal of Clinical Psychology
|March 6, 2014
Summary
Psychological treatments for depression significantly improved insomnia symptoms in adults. However, individuals with severe depression may need additional insomnia-specific interventions for substantial sleep relief.
Area of Science:
- Psychiatry
- Sleep Medicine
- Clinical Psychology
Background:
- Insomnia is a common comorbid symptom in adults diagnosed with depression.
- Effective management of depression is crucial for improving overall patient well-being, including sleep quality.
Purpose of the Study:
- To evaluate the impact of manualized psychological treatments for depression on comorbid insomnia symptoms.
- To determine if depression treatment alone is sufficient for alleviating sleep disturbances across different depression severity levels.
Main Methods:
- Archival data from 14 studies (N=910) involving adults with depression were analyzed.
- Hierarchical linear modeling was employed to assess treatment efficacy.
- Comparison between participants receiving psychological depression treatment and those who did not.
Main Results:
- Psychological treatments for depression led to significant improvements in overall sleep quality.
- Participants experienced notable relief from early-, middle-, and late-night insomnia symptoms.
- The degree of sleep improvement correlated with depression severity.
Conclusions:
- Psychological interventions for depression can effectively reduce insomnia symptoms in individuals with average or lower levels of depression.
- More severe depressive symptoms may not fully resolve sleep disturbances, suggesting a need for adjunctive insomnia-focused treatments.
- Further research is warranted to explore integrated treatment approaches for comorbid depression and insomnia.
Related Concept Videos
01:19Management of Insomnia
785
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
785
01:27Insomnia
620
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
620
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
981
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
981
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.9K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.9K